News and Analysis

Tissue-agnostic cancer drug pipeline grows, despite doubts

The FDA could soon approve the first drug developed explicitly for a tissue-agnostic cancer indication, but biological complexity may limit this approach.

  • Subscribe to Nature Reviews Drug Discovery for full access:

    $265

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Authors

  1. Search for Ken Garber in: